达托霉素
万古霉素
菌血症
金黄色葡萄球菌
脂肽
医学
抗生素
抗菌剂
微生物学
葡萄球菌感染
微球菌科
抗菌剂
药理学
细菌
生物
遗传学
作者
J. Keith Smith,G. Cobbs,Ricardo Eugenio Dill,D. M. Lyon,Adrienne Graves,K. Avent
出处
期刊:Chemotherapy
[S. Karger AG]
日期:1990-01-01
卷期号:36 (6): 428-434
被引量:13
摘要
Daptomycin (LY 146032), a new lipopeptide antimicrobial agent with activity against gram-positive bacteria, was compared to vancomycin in the treatment of staphylococcal bacteremia in a murine model. Two hundred and ninety-nine mice were inoculated with 1 x 108 bacteria by the tail vein, and treatment was begun 3 days later. Two dosage regimens of each drug were used: 10 mg/kg and 5 mg/kg administered every 12 h for 14 days. A control group received no therapy. Survival was determined 31 days after inoculation. There was no significant difference in survival in any of the four treatment groups. The survival in all treatment groups was significantly greater than in the control group. Serum levels of daptomycin remained longer in the therapeutic range than serum levels of vancomycin. In the murine model of staphylococcal disease, daptomycin treatment was as effective as treatment with vancomycin.
科研通智能强力驱动
Strongly Powered by AbleSci AI